Buprenorphine Forms for Opioid Use Disorder (VA-BRAVE Trial)

"Subcutaneous buprenorphine is commonly utilized to address opioid dependency, however it may also be beneficial in ameliorating pruritus, pain and septic shock."

"The Minneapolis VA Health Care System in Minnesota, Dayton VA Medical Center in Ohio, and Hampton VA Medical Centre in Virginia are the three primary sites for this clinical trial. Additionally, there are an additional 18 locations offering enrollment opportunities."

"Presently, there are 56 Injectable subcutaneous buprenorphine trials in progress with 13 Phase 3 studies. These clinical experiments originate primarily from White River Junction, Vermont but can also be found at 235 other medical sites around the world."

"Data from clinical trials and other sources show that injectable subcutaneous buprenorphine is a safe therapy, thus it has earned an estimated safety rating of 3."

"The purpose of this trial, monitored over a period of 52 weeks, is to promote opioid abstinence. Secondary objectives include gauging the intensity of an individual's craving for opioids via a 10-point Likert scale, assessing Post Traumatic Stress Disorder by employing the DSM-5 checklist and determining if any other addictive substances have been consumed using both Timeline Followback self-reporting measures as well as urine toxicology results."

"Affirmative. The information available on clinicaltrials.gov confirms this investigation is actively seeking participants with an initial posting date of November 3rd 2020, and the last update was June 1st 2022. There are 18 enrolment sites across the US searching for 952 individuals to participate in their trial."

"952 participants who meet the eligibility criteria are sought for this study. Qualifying patients may join from Minneapolis VA Health Care System, Minneapolis, MN or Dayton VA Medical Center, Dayton, OH in Minnesota and Ohio respectively."